NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: MEDICAMEQ · data 2026-10-31
Medicamen Biotech Limited
In plain words
Price: 42.8% below its 52-week high of ₹447.65.
Delivery: 48.4% of traded shares were kept for delivery over the last 10 sessions, against 63.9% over the last 60.
Latest results: a net profit of ₹2 cr for the quarter ended Dec 2023.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹203 cr |
| Net profit (last 12 months) | ₹11 cr |
| Sales growth, 3 years (yearly) | 12.0% |
| Profit growth, 3 years (yearly) | -13.4% |
At a glance
Promoters 40.5%, pledged 0.0%, institutions 0.6%.
P/E 31.3, dividend yield 0.4%. Price relative to earnings and book value (low is cheaper, not better).
ROE 3.9%, ROCE 5.5%, operating margin 6.0%: how much profit it earns on the money it uses.
Debt/equity 0.18, Profit growth -13.4% and sales growth 12.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (3.9%).
- Profit fell 13.4% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q3 FY24)
MEDICAMEQ Q3 FY24 results (consolidated figures, as filed on NSE).
Revenue was ₹46.5 crore.
Net profit was ₹2.03 crore.
Operating margin was 10.5%.
EPS was ₹1.6.
MEDICAMEQ के Q3 FY24 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹46.5 करोड़।
शुद्ध मुनाफ़ा: ₹2.03 करोड़।
ऑपरेटिंग मार्जिन: 10.5%।
EPS: ₹1.6।
MEDICAMEQના Q3 FY24 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹46.5 કરોડ.
ચોખ્ખો નફો: ₹2.03 કરોડ.
ઓપરેટિંગ માર્જિન: 10.5%.
EPS: ₹1.6.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 18 Sept 26Dividend Dividend ₹1 (ex-date) -8.1% next session
- 19 Sept 25Dividend Dividend ₹1 (ex-date) -2.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2023 | ₹47 cr | ₹2 cr | — | 10.5% | 1.6 |
| Mar 2023 | ₹39 cr | ₹4 cr | — | 16.8% | 3.03 |
Shareholding trend
| Holder | Jun 2025 |
|---|---|
| Promoters | 40.46% |
| Foreign institutions (FII) | 0.00% |
| Domestic institutions (DII) | 0.64% |
| Mutual funds | — |
| Retail investors | 21.83% |
| Number of shareholders | 10,808 |
Common questions
What was Medicamen Biotech Limited's latest quarterly profit?
Medicamen Biotech Limited reported a net profit of ₹2 cr for the quarter ended Dec 2023, on revenue of ₹47 cr.
How much do promoters hold in Medicamen Biotech Limited?
Promoters held 40.46% of Medicamen Biotech Limited at the end of Jun 2025, with 0.00% of promoter shares pledged.
Is Medicamen Biotech Limited debt-free?
Its latest reported debt-to-equity ratio is 0.18.
What is Medicamen Biotech Limited's P/E ratio?
About 31.3, based on the last 12 months' earnings and a price of ₹256.2 (data 2026-10-31).
What is the 52-week high and low of Medicamen Biotech Limited?
The 52-week high is ₹447.65 and the 52-week low is ₹212.4.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Medicamen Biotech Limited | ₹256.2 | ₹347 cr | 31.3 | — | 3.9% | 5.5% | 0.18 | -27.6% |
| Infinium Pharmachem Ltd. | ₹281 | ₹438 cr | 36 | 3.6 | 10.5% | 13.5% | 0.19 | +8.0% |
| Albert David Ltd | ₹762.8 | ₹435 cr | 19.3 | — | -0.4% | 0.3% | 0.08 | -11.0% |
| Jenburkt Pharmaceuticals Ltd | ₹853.6 | ₹377 cr | 11.5 | — | 18.8% | 22.7% | 0.01 | -18.1% |
| Aarey Drugs & Pharmaceuticals Ltd. | ₹106.26 | ₹298 cr | 72.4 | — | 2.7% | 6% | 0.33 | +15.4% |
| Ambalal Sarabhai Enterprises Limited | ₹34.99 | ₹268 cr | 19.8 | — | 11.9% | 9.4% | 0.36 | +8.3% |
Compare MEDICAMEQ with INFINIUM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MEDICAMEQ in NSE Scanner →